Related Experiment Videos
[Clinical study on ivermectin against Strongyloides stercoralis]
1First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus.
Summary
Ivermectin (IVM) effectively treats strongyloidiasis, achieving high cure rates in 54 patients. Mild, transient side effects were observed, confirming IVM
Area of Science:
- Infectious Diseases
- Parasitology
- Pharmacology
Context:
- Strongyloidiasis is a neglected tropical disease caused by parasitic roundworms.
- Ivermectin is an antiparasitic drug with established efficacy against various helminth infections.
Purpose:
- To evaluate the efficacy and safety of a two-dose regimen of ivermectin for treating strongyloidiasis.
- To assess the cure rates and adverse events associated with ivermectin therapy in a larger patient cohort.
Summary:
- A study involving 54 strongyloidiasis patients demonstrated high cure rates with a two-dose ivermectin regimen.
- The initial treatment achieved a 92.5% cure rate, increasing to 96.0% after a second dose two weeks later.
- Adverse events were mild and transient, including diarrhea, constipation, and itching, with no need for intervention.
Impact:
- Ivermectin is confirmed as a safe and effective treatment option for strongyloidiasis.
- The findings support the use of ivermectin in clinical practice for managing this parasitic infection.
- Further research may explore optimal dosing strategies and long-term outcomes.